UK MHRA Takes Companies To Task Over Trial Safety Information Reporting
Executive Summary
Sponsors of clinical trials in the EU have recently been inundated with objections from regulators for incorrectly managing their clinical trial reference safety information, which in turn has resulted in these trials being significantly delayed. A UK MHRA inspector discusses some of the common issues identified during inspections on this front.
You may also be interested in...
Incorrect Use Of Reference Safety Info Still An Issue, Says UK MHRA
UK good clinical practice inspectors are continuing to detect critical shortcomings relating to clinical trials safety and the management of reference safety information.
How To Manage Pharmacovigilance Inspections In A Globalized World
As companies undergo pharmacovigilance inspections from a growing multitude of regulatory authorities from around the globe, a senior pharmaceutical industry executive discusses how her company has been handling this complex and challenging task.
Un-blinding, Pharmacovigilance Issues Among Top GCP Findings, Says UK Inspector
A UK good clinical practice inspector discusses common findings issued in relation to clinical trials as well as the challenges posed by new technologies, such as use of apps on smartphones and electronic patient diaries to record outcomes.